scholarly journals Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery

2017 ◽  
Vol 2 (1) ◽  
pp. 43-57 ◽  
Author(s):  
Marcus J. Rohovie ◽  
Maya Nagasawa ◽  
James R. Swartz
Keyword(s):  
Next Generation ◽  
Virus Like Particles ◽  
Therapeutic Delivery ◽  
Targeted Therapeutic

scholarly journals HPV-Impfstoffe – zugelassene Vakzinen und experimenteller RG1-VLP-Impfstoff der nächsten Generation

hautnah ◽  
2021 ◽  
Author(s):  
Christina Schellenbacher ◽  
Bettina Huber ◽  
Saeed Shafti-Keramat ◽  
Reinhard Kirnbauer
Keyword(s):  
High Risk ◽  
Phase I ◽  
Low Risk ◽  
Next Generation ◽  
Virus Like Particles

ZusammenfassungInfektionen mit >12 sexuell übertragbaren genitalen „high-risk“ (hr) humanen Papillomviren (HPV) sind hauptverantwortlich für anogenitale Karzinome, insbesondere Zervix- und Analkarzinome sowie oropharyngeale Karzinome, insgesamt für 5 % der Karzinome weltweit. Genitale „low-risk“ (lr) HPV und kutane HPV verursachen Anogenitalwarzen (Kondylome) bzw. Hautwarzen, kutane Genus β‑HPV sind ein potenzieller Kofaktor für die Entwicklung nichtmelanozytärer Hautkarzinome in Immunsupprimierten. Die zugelassenen HPV-Vakzinen sind Spaltimpfstoffe bestehend aus leeren Hauptkapsidproteinhüllen (L1-virus-like particles, VLP). Die prophylaktische Impfung mit dem modernen nonavalenten Impfstoff Gardasil‑9 (HPV6/11/16/18/31/33/45/52/58) verhindert persistierende Infektionen mit Typen, die bis zu 90 % der Zervixkarzinome und Kondylome verursachen. Der Impfschutz ist vorwiegend typenspezifisch, daher besteht kein Schutz gegen Infektionen mit den übrigen genitalen hrHPV oder Hauttypen. RG1-VLP ist ein experimenteller „next generation“-Impfstoff, bestehend aus HPV16L1-VLP, welche ein Kreuzneutralisierungs-Epitop des HPV16 Nebenkapsidproteins L2 („RG1“; Aminosäuren 17–36) repetitiv (360×) an der Oberfläche tragen. Eine Vakzinierung mit RG1-VLP schützt im Tierversuch gegen experimentelle Infektionen mit allen relevanten genitalen hrHPV (~96 % aller Zervixkarzinome), lrHPV (~90 % der Kondylome) sowie gegen einige kutane und β‑HPV. Präklinische Daten zeigen langanhaltende Protektion ohne Boosterimmunisierung ein Jahr nach der Impfung sowie Wirksamkeit nach nur 2 Dosen. Auch in lyophilisierter, thermostabiler Form bleibt die Immunogenität der RG1-VLP erhalten. Eine Phase-I-Studie ist mit Unterstützung des US NCI/NIH in Vorbereitung. Der vorliegende Artikel diskutiert Fragestellungen zur HPV-Impfstoffoptimierung und präsentiert den pan-HPV-Impfstoffkandidat RG1-VLP.

scholarly journals Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Mohammad W. Bahar ◽  
Claudine Porta ◽  
Helen Fox ◽  
Andrew J. Macadam ◽  
Elizabeth E. Fry ◽  
...  
Keyword(s):  
Significant Risk ◽  
Next Generation ◽  
Wild Type ◽  
Inactivated Polio Vaccine ◽  
Vaccination Programs ◽  
Virus Like Particles ◽  
Mammalian Expression ◽  
Cryo Electron Microscopy ◽  
Alternative Expression ◽  
Antibody Titres

AbstractGlobal vaccination programs using live-attenuated oral and inactivated polio vaccine (OPV and IPV) have almost eradicated poliovirus (PV) but these vaccines or their production pose significant risk in a polio-free world. Recombinant PV virus-like particles (VLPs), lacking the viral genome, represent safe next-generation vaccines, however their production requires optimisation. Here we present an efficient mammalian expression strategy producing good yields of wild-type PV VLPs for all three serotypes and a thermostabilised variant for PV3. Whilst the wild-type VLPs were predominantly in the non-native C-antigenic form, the thermostabilised PV3 VLPs adopted the native D-antigenic conformation eliciting neutralising antibody titres equivalent to the current IPV and were indistinguishable from natural empty particles by cryo-electron microscopy with a similar stabilising lipidic pocket-factor in the VP1 β-barrel. This factor may not be available in alternative expression systems, which may require synthetic pocket-binding factors. VLPs equivalent to these mammalian expressed thermostabilized particles, represent safer non-infectious vaccine candidates for the post-eradication era.

scholarly journals Systems approaches to design of targeted therapeutic delivery

2015 ◽  
Vol 7 (5) ◽  
pp. 253-265 ◽  
Author(s):  
Jacob W. Myerson ◽  
Jacob S. Brenner ◽  
Colin F. Greineder ◽  
Vladimir R. Muzykantov
Keyword(s):  
Systems Approaches ◽  
Therapeutic Delivery ◽  
Targeted Therapeutic

scholarly journals Intellectual property issues in nanotechnology

1969 ◽  
Vol 13 (3) ◽  
Author(s):  
Lars Genieser ◽  
Michael Gollin
Keyword(s):  
Intellectual Property ◽  
Medical Applications ◽  
Nanoscale Materials ◽  
Therapeutic Delivery ◽  
Wide Range ◽  
The Us ◽  
Antitrust Laws ◽  
Commercially Important ◽  
Delivery Vehicles ◽  
Targeted Therapeutic

Emerging nanotechnologies have the potential to impact a wide range of commercially important bioscience and medical applications. For example, researchers are developing nanoscale materials as diagnostic probes and targeted therapeutic delivery vehicles. By filing patents, companies can protect their intellectual property and leverage their developments over the marketplace in a way that is consistent with antitrust laws. Policies and doctrines of the US Patent and Trademark Office pertaining to nanotechnology continue to develop. Companies must be aware of challenges and strategies particular to nanotechnology in seeking patents in order to maximise the value of their innovations.

Theranostic liposomes containing conjugated polymer dots and doxorubicin for bio-imaging and targeted therapeutic delivery

RSC Advances ◽  
2016 ◽  
Vol 6 (3) ◽  
pp. 1945-1957 ◽  
Author(s):  
Man Ma ◽  
Mingzhu Lei ◽  
Xiaoxiao Tan ◽  
Fengping Tan ◽  
Nan Li
Keyword(s):  
Conjugated Polymer ◽  
Therapeutic Delivery ◽  
Polymer Dots ◽  
Bio Imaging ◽  
Targeted Therapeutic

This work was devoted to the development of a lipid-based theranostic nanoparticle able to simultaneously host conjugated polymer dots, doxorubicin (Dox) and folate acid (FA).

Sign in / Sign up

Export Citation Format

Share Document